Manama: The National Health Regulatory Authority (NHRA) has announced the withdrawal and suspension of registration of the pharmaceutical product “PROTON 40mg E.C TABLET – PROTON 20mg E.C TABLET”, produced by the Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO). The move is based on the warning issued by the Saudi Food and Drug Authority (SFDA) on March 12, 2021. The NHRA indicated said that it has withdrawn the medicine from the Kingdom, and suspended its registration because it does not match the original product. The NHRA recommended the health authorities to withdraw the product as soon as it is available to them, calling on the medicine users to contact their doctors to receive the alternative medication.
Trending
- HM King commends government’s efforts in ensuring success of Ashoora
- Saudi Arabia underscores importance of UN Charter and multilateral cooperation
- Saudi, Omani foreign ministers discuss regional developments
- Dr. Al Rumaihi condemns Iranian drone attack targeting Bahrain
- KHGC organises conference on coexistence and religious diversity in cooperation with Cyprus
- HH Shaikh Nasser bin Hamad attends the Golden Plate Award honouree reception
- Bahrain Government upgrades 88 services across 18 public entities
- Bahrain and UK sign agreement to enhance customs cooperation
